Evaluation of recurrence risk after organ-sparing treatment of breast cancer depending on biological subtype of the tumor
https://doi.org/10.18027/2224-5057-2015-3-34-38
Abstract
In this study, based on the results of IHC of patients with reсurrence of breast cancer, the most often found molecular subtypes were analyzed and assessed their role in the development of local recurrence. Analysis of risk of recurrence of breast cancer was conducted in accordance with the molecular features of the tumor, which include the expression of estrogen receptor, progesterone receptor gene and the expression of human epidermal growth factor – HER2 / neu and proliferation activity index Ki 67. The study found that the majority of primary tumors, followed by recurrence are triple negative type (42%). Also we found the change in morphological parameters of recurrent tumor. Thus, in most cases of recurrence proliferative activity index increases by an average of 12%, about 30% of tumors have changed their morphological status.
About the Authors
S. M. DEMIDOV
Head of Ekaterinburg Mammology Center
Ural State Medical University, City Hospital No. 40 in Ekaterinburg
Russian Federation
Russian Federation
doctor of medical sciences, professor
Chair of the Department of oncology and medical radiology
S. V. SAZONOV
Ural State Medical University
Institute of medical cellular technologies in Ekaterinburg
Russian Federation
Russian Federation
doctor of medical sciences, professor, Chair of the Department
of histology
head of pathomorphologcal laboratory
D. A. DEMIDOV
Ural State Medical University
City Hospital No. 40 in Ekaterinburg
Russian Federation
Russian Federation
candidate of medical sciences, associate professor of Department of oncology and medical radiology
surgeon
A. Y. SUNTSOVA
Ural State Medical University
Russian Federation
5th year student
Russian Federation
5th year student
T. O. IRIKH
City Hospital No. 40 in Ekaterinburg
Russian Federation
surgeon
Russian Federation
surgeon
References
1. Ермилова В. Д. Роль современной патоморфологии в характеристике рака молочной железы. Журнал Практическая онкология, Т. 3, № 1–2002. Ermilova V. D. The role of modern pathomorphology in breast cancer characteristics. Practical Oncology, vol.3, № 1–2002.
2. Иванцов А. О., Мацко Д. Е. Возможности иммуногистохимического исследования в диагностике опухолей. Журнал Практическая онкология, Т. 12, № 4–2011 г. Ivantsov A. O., Matsko D. E. Capabilities of immunehistochemical investigation in tumors diagnostics. Practical Oncology, vol.12, № 4–2011.
3. Иммуногистохимические методы, руководство (пер. с англ. под ред. Г. А. Франка и П. Г. Малькова) // М., 2011–224 с. Immunehistochemical methods. The guideline. M., 2011 – p224.
4. Петрова Г. В., Старинский В. И., Чиссов В. В. Состояние онкологической помощи населению России в 2013 г.: М.: Изд-во ФИАН, 2014 г. Petrova G. V., Starinskiy V. I., Chissov V. V. Current status of oncologic healthcare in Russia in 2013. M. – 2014.
5. Практические рекомендации по лечению злокачественных опухолей Российского общества клинической онкологии, 2014 г. Practical recommendations in treatment of malignant tumors. Russian Society of Clinical Oncology. 2014.
6. Almasri N. M., Al Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma//Breast Cancer Res. –2005. – Vol.7 (5). –P. 598–604.
7. Jones R. L., Salter J., A’Hern R. et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer // Breast Cancer Res Treat. 2009. Vol. 116 (1). Р. 53–68.
8. Katz A., Strom E., Bucholz T. et.al. Locoregional Reccurence Patterns After Mastectomy and Doxorubicin-based Chemotherapy: Implications for Postoperative Irradiation. // J. Clin. Oncol. – 2000, 18:2817–2827.
9. Dendukuri N., PhD, Research Scientist, Technology Assessment Unit, Brophy J., Divisions of Cardiology and Clinical Epidemiology, Department of Medicine, MUHC Testing for HER2 positive breast cancer: a cost effectiveness analysys, report 23, 2006.
10. Penault-Llorca F., Cayre A., Bouchet Mishellany F. et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003; 22 (6): 1319–25.
11. http://netoncology.ru/press/articles/561/630/
Review
For citations:
DEMIDOV S.M., SAZONOV S.V., DEMIDOV D.A., SUNTSOVA A.Y., IRIKH T.O. Evaluation of recurrence risk after organ-sparing treatment of breast cancer depending on biological subtype of the tumor. Malignant tumours. 2015;(3):34-38. (In Russ.) https://doi.org/10.18027/2224-5057-2015-3-34-38
Views:
1020
Email this article 